Lirilumab

Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2/3.

This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb.

Clinical trials
A phase 2 clinical trial for acute myeloid leukemia (AML) was terminated early ("failed") in 2017.

It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN), but it may be abandoned.

nine clinical trials of lirilumab are registered as active.